Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| ciliated cell | 7 studies | 29% ± 13% | |
| B cell | 7 studies | 19% ± 4% | |
| CD16-negative, CD56-bright natural killer cell, human | 7 studies | 18% ± 2% | |
| natural killer cell | 6 studies | 21% ± 3% | |
| plasmacytoid dendritic cell | 6 studies | 22% ± 6% | |
| CD16-positive, CD56-dim natural killer cell, human | 5 studies | 18% ± 2% | |
| endothelial cell | 5 studies | 23% ± 8% | |
| epithelial cell | 5 studies | 36% ± 13% | |
| classical monocyte | 4 studies | 21% ± 4% | |
| CD8-positive, alpha-beta T cell | 4 studies | 17% ± 1% | |
| non-classical monocyte | 3 studies | 26% ± 6% | |
| precursor B cell | 3 studies | 19% ± 1% | |
| pericyte | 3 studies | 18% ± 3% | |
| fibroblast | 3 studies | 21% ± 2% | |
| dendritic cell | 3 studies | 32% ± 12% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| prostate | 100% | 2333.76 | 245 / 245 | 100% | 16.77 | 502 / 502 |
| stomach | 100% | 1772.61 | 359 / 359 | 100% | 9.01 | 286 / 286 |
| brain | 100% | 2738.96 | 2640 / 2642 | 100% | 24.04 | 705 / 705 |
| thymus | 100% | 2540.85 | 653 / 653 | 100% | 16.47 | 604 / 605 |
| breast | 100% | 1877.26 | 459 / 459 | 99% | 11.64 | 1112 / 1118 |
| bladder | 100% | 2631.10 | 21 / 21 | 99% | 9.36 | 500 / 504 |
| pancreas | 100% | 1287.45 | 327 / 328 | 99% | 8.31 | 177 / 178 |
| uterus | 100% | 2211.56 | 170 / 170 | 99% | 10.58 | 454 / 459 |
| kidney | 100% | 1591.09 | 89 / 89 | 99% | 10.33 | 891 / 901 |
| lung | 99% | 1624.11 | 575 / 578 | 99% | 9.96 | 1148 / 1155 |
| intestine | 100% | 2817.99 | 966 / 966 | 98% | 8.59 | 519 / 527 |
| skin | 100% | 1352.71 | 1807 / 1809 | 98% | 12.95 | 463 / 472 |
| esophagus | 100% | 2448.88 | 1443 / 1445 | 97% | 7.48 | 178 / 183 |
| ovary | 100% | 1745.12 | 180 / 180 | 97% | 6.86 | 415 / 430 |
| adrenal gland | 100% | 1854.94 | 258 / 258 | 93% | 13.10 | 213 / 230 |
| liver | 99% | 729.00 | 223 / 226 | 91% | 5.90 | 368 / 406 |
| adipose | 100% | 2047.56 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| blood vessel | 100% | 2681.07 | 1335 / 1335 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 13.98 | 29 / 29 |
| muscle | 100% | 7348.04 | 803 / 803 | 0% | 0 | 0 / 0 |
| spleen | 100% | 1856.61 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 8.67 | 45 / 45 |
| ureter | 0% | 0 | 0 / 0 | 100% | 5.59 | 1 / 1 |
| heart | 98% | 2134.23 | 847 / 861 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 96% | 10.69 | 77 / 80 |
| peripheral blood | 85% | 914.49 | 793 / 929 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_1900272 | Biological process | negative regulation of long-term synaptic potentiation |
| GO_0048167 | Biological process | regulation of synaptic plasticity |
| GO_0043083 | Cellular component | synaptic cleft |
| GO_0045202 | Cellular component | synapse |
| GO_0005515 | Molecular function | protein binding |
| Gene name | C22orf39 |
| Protein name | Synaptic plasticity regulator PANTS (Plasticity-associated neural transcript short) |
| Synonyms | |
| Description | FUNCTION: Negatively regulates long-term potentiation and modulates adult synaptic plasticity. Stabilizes the interaction of RTN4 isoform A/Nogo-A with its receptors, inhibiting clustering of postsynaptic AMPA receptors at synaptic sites. Upon neuronal stimulation, degraded at synapses, reducing RTN4 signaling and allowing AMPA receptor clustering at individual synapses. . |
| Accessions | ENST00000399562.9 [Q6P5X5-1] ENST00000399568.5 [Q6P5X5-2] ENST00000509549.5 E0CX16 Q6P5X5 |